These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35152722)

  • 41. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1.
    Tashiro H; Sauer T; Shum T; Parikh K; Mamonkin M; Omer B; Rouce RH; Lulla P; Rooney CM; Gottschalk S; Brenner MK
    Mol Ther; 2017 Sep; 25(9):2202-2213. PubMed ID: 28676343
    [TBL] [Abstract][Full Text] [Related]  

  • 42. B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia.
    Fan S; Wang T; You F; Zhang T; Li Y; Ji C; Han Z; Sheng B; Zhai X; An G; Meng H; Yang L
    Eur J Med Res; 2023 Mar; 28(1):129. PubMed ID: 36941687
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.
    Lichtman EI; Du H; Shou P; Song F; Suzuki K; Ahn S; Li G; Ferrone S; Su L; Savoldo B; Dotti G
    Clin Cancer Res; 2021 Jun; 27(11):3141-3153. PubMed ID: 33531429
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia.
    Ganesan R; Chennupati V; Ramachandran B; Hansen MR; Singh S; Grewal IS
    Leukemia; 2021 Aug; 35(8):2274-2284. PubMed ID: 33526858
    [TBL] [Abstract][Full Text] [Related]  

  • 45. T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia.
    Mardiros A; Forman SJ; Budde LE
    Curr Opin Hematol; 2015 Nov; 22(6):484-8. PubMed ID: 26457961
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
    Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells.
    Wang Y; Xu Y; Li S; Liu J; Xing Y; Xing H; Tian Z; Tang K; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2018 May; 11(1):60. PubMed ID: 29716633
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells.
    Jin X; Xie D; Sun R; Lu W; Xiao X; Yu Y; Meng J; Zhao M
    Oncoimmunology; 2023; 12(1):2248826. PubMed ID: 37645216
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.
    O'Hear C; Heiber JF; Schubert I; Fey G; Geiger TL
    Haematologica; 2015 Mar; 100(3):336-44. PubMed ID: 25480499
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts.
    Gertner-Dardenne J; Castellano R; Mamessier E; Garbit S; Kochbati E; Etienne A; Charbonnier A; Collette Y; Vey N; Olive D
    J Immunol; 2012 May; 188(9):4701-8. PubMed ID: 22467661
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia.
    Sánchez Martínez D; Tirado N; Mensurado S; Martínez-Moreno A; Romecín P; Gutiérrez Agüera F; Correia DV; Silva-Santos B; Menéndez P
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36162920
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MUC1-Tn-targeting chimeric antigen receptor-modified Vγ9Vδ2 T cells with enhanced antigen-specific anti-tumor activity.
    Zhai X; You F; Xiang S; Jiang L; Chen D; Li Y; Fan S; Han Z; Zhang T; An G; Zhang B; Chen Y; Meng H; Yang L
    Am J Cancer Res; 2021; 11(1):79-91. PubMed ID: 33520361
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
    Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
    Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
    Front Immunol; 2020; 11():580328. PubMed ID: 33384686
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia.
    Caulier B; Joaquina S; Gelebart P; Dowling TH; Kaveh F; Thomas M; Tandaric L; Wernhoff P; Katyayini NU; Wogsland C; Gjerstad ME; Fløisand Y; Kvalheim G; Marr C; Kobold S; Enserink JM; Gjertsen BT; McCormack E; Inderberg EM; Wälchli S
    Cell Rep Med; 2024 Jun; 5(6):101572. PubMed ID: 38754420
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells.
    Hebbar N; Epperly R; Vaidya A; Thanekar U; Moore SE; Umeda M; Ma J; Patil SL; Langfitt D; Huang S; Cheng C; Klco JM; Gottschalk S; Velasquez MP
    Nat Commun; 2022 Jan; 13(1):587. PubMed ID: 35102167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2
    Dai Q; Han P; Qi X; Li F; Li M; Fan L; Zhang H; Zhang X; Yang X
    Front Immunol; 2020; 11():539654. PubMed ID: 33281809
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CD123 CAR T cells for the treatment of myelodysplastic syndrome.
    Stevens BM; Zhang W; Pollyea DA; Winters A; Gutman J; Smith C; Budde E; Forman SJ; Jordan CT; Purev E
    Exp Hematol; 2019 Jun; 74():52-63.e3. PubMed ID: 31136781
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response.
    Foster JB; Choudhari N; Perazzelli J; Storm J; Hofmann TJ; Jain P; Storm PB; Pardi N; Weissman D; Waanders AJ; Grupp SA; Karikó K; Resnick AC; Barrett DM
    Hum Gene Ther; 2019 Feb; 30(2):168-178. PubMed ID: 30024272
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
    Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
    Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.